Additivity of nebivolol/valsartan single‐pill combinations versus other single‐pill combinations for hypertension. Issue 1 (5th November 2017)

• Record Type: Journal Article
• Authors: Ishak, Jack; Rael, Michael; Punzi, Henry; Gradman, Alan; Anderson, Lynn M.; Patel, Mehul; Ali, Sanjida; Ferguson, William; Neutel, Joel
• Is Part Of: Journal of clinical hypertension. Volume 20:Issue 1(2018)
• Page Start: 143
• Page End: 149
• Publication Date: 2017-11-05
• Subjects: antihypertensive agents -- drug combination -- efficacy -- hypertension -- nebivolol -- valsartan; Hypertension -- Periodicals; 616.132
• DOI: 10.1111/jch.13132
• Languages: English
• ISSNs: 1524-6175

Abstract

Abstract : The single‐pill combination (SPC) comprising nebivolol (5 mg), a vasodilatory β1 ‐selective antagonist/β3 ‐agonist, and valsartan (80 mg), a renin‐angiotensin‐aldosterone system inhibitor, is the only Food and Drug Administration–approved β‐blocker/renin‐angiotensin‐aldosterone system inhibitor SPC for hypertension. Additive effects of four nebivolol/valsartan SPC doses (5 mg/80 mg, 5/160 mg, 10/160 mg, 10/320 mg nebivolol/valsartan) were compared with five Food and Drug Administration–approved non–β‐blocker/renin‐angiotensin‐aldosterone system inhibitor SPCs (aliskiren/hydrochlorothiazide, aliskiren/amlodipine, valsartan/amlodipine, aliskiren/valsartan, and telmisartan/amlodipine). Additivity is the ratio of placebo‐adjusted SPC blood pressure (BP) reduction to the placebo‐adjusted monotherapy component BP reduction sums. A weighted average of comparator scores was calculated and compared vs nebivolol/valsartan. Additivity ratio scores for nebivolol/valsartan SPCs (diastolic BP range: 0.735–0.866; systolic BP range: 0.717–0.822) were similar to the comparator weighted average (diastolic BP: 0.837; systolic BP: 0.825). Among the nebivolol/valsartan SPCs, 5/80 mg had the greatest additivity (diastolic BP: 0.866; systolic BP: 0.822). BP reduction contributions with monotherapy were similar for nebivolol/valsartan 5/80 mg SPC. Additivity scores for nebivolol/valsartan and select non–β‐blocker/renin‐angiotensin‐aldosterone system inhibitor SPCs were comparable.